公开(公告)号：US20240376221A1

公开(公告)日：2024-11-14

申请号：US18660672

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11459395B2

公开(公告)日：2022-10-04

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz ,  Edward Van den Brink ,  Dennis Verzijl

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20240392032A1

公开(公告)日：2024-11-28

申请号：US18617483

申请日：2024-03-26

Applicant: Genmab A/S

Inventor： David SATIJN ,  Esther C.W. Breij ,  Bart E.C.G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11130819B2

公开(公告)日：2021-09-28

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US10201607B2

公开(公告)日：2019-02-12

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US11261254B1

公开(公告)日：2022-03-01

申请号：US17494545

申请日：2021-10-05

Applicant: GENMAB A/S

Inventor： Louise Koopman ,  Patrick Engelberts ,  Dennis Verzijl ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Sieto Bosgra ,  Frederikke L. Egerod ,  David Satijn ,  Esther C. W. Breij

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11008399B2

公开(公告)日：2021-05-18

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US10765743B2

公开(公告)日：2020-09-08

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther Breij ,  David Satijn ,  Edward Norbert Van Den Brink ,  Dennis Verzijl ,  Rob N. De Jong ,  Paul Parren ,  Riemke Van Dijkhuizen Radersma

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K39/00 ,  C07K16/30

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US11970544B2

公开(公告)日：2024-04-30

申请号：US17353087

申请日：2021-06-21

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/565

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.